{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:32:50Z","timestamp":1793046770406,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":279,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.lrr.2026.100615","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:31:24Z","timestamp":1791473484000},"page":"100615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The prognostic value of KRAS, NRAS, and BRAF genes mutations in patients with newly diagnosed multiple myeloma"],"prefix":"10.1016","volume":"26","author":[{"given":"Phuong Thao","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5216-2282","authenticated-orcid":false,"given":"Hoang Viet","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5473-557X","authenticated-orcid":false,"given":"Minh Phuong","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lrr.2026.100615_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.seminoncol.2025.152390","article-title":"Multiple myeloma: insights into underlying mechanisms, advances in diagnostic and therapeutic modalities","volume":"52","author":"Yadav","year":"2025","journal-title":"Semin. Oncol."},{"issue":"6","key":"10.1016\/j.lrr.2026.100615_bib0002","first-page":"812","article-title":"Review of multiple myeloma genetics including effects on prognosis, response to treatment, and diagnostic workup","volume":"12","author":"Wiedmeier-Nutor","year":"2022","journal-title":"Life (Basel)"},{"issue":"2","key":"10.1016\/j.lrr.2026.100615_bib0003","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/cells10020336","article-title":"Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications","volume":"10","author":"Cardona-Benavides","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.lrr.2026.100615_bib0004","doi-asserted-by":"crossref","first-page":"463","DOI":"10.37349\/etat.2022.00095","article-title":"A personalized molecular approach in multiple myeloma: the possible use of RAF\/RAS\/MEK\/ERK and BCL-2 inhibitors","volume":"3","author":"Raimondi","year":"2022","journal-title":"Explor. Target. Antitumor. Ther."},{"issue":"1","key":"10.1016\/j.lrr.2026.100615_bib0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple myeloma: signaling pathways and targeted therapy","volume":"5","author":"Lu","year":"2024","journal-title":"Mol. Biomed."},{"issue":"3","key":"10.1016\/j.lrr.2026.100615_bib0006","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cpt.2023.12.004","article-title":"Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technology","volume":"2","author":"Wang","year":"2024","journal-title":"Cancer Pathog. Ther."},{"issue":"1","key":"10.1016\/j.lrr.2026.100615_bib0007","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3960\/jslrt.24077","article-title":"Impact of NRAS mutation on efficacy of triplet induction therapy in newly diagnosed multiple myeloma","volume":"65","author":"Mishima","year":"2025","journal-title":"J. Clin. Exp. Hematop."},{"issue":"5","key":"10.1016\/j.lrr.2026.100615_bib0008","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/hon.3208","article-title":"Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma","volume":"41","author":"Perroud","year":"2023","journal-title":"Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.lrr.2026.100615_bib0009","doi-asserted-by":"crossref","first-page":"81","DOI":"10.17650\/1818-8346-2025-20-4-81-91","article-title":"KRAS, NRAS, BRAF genes mutations in tumor cells of various localizations and their impact on the treatment outcomes of patients with multiple myeloma","volume":"20","author":"Soloveva","year":"2025","journal-title":"Oncohematology"},{"issue":"Supplement 1","key":"10.1016\/j.lrr.2026.100615_bib0010","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1182\/blood-2025-3989","article-title":"Systematic analysis of gene mutations in Chinese multiple myeloma patients","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.lrr.2026.100615_bib0011","doi-asserted-by":"crossref","first-page":"14293","DOI":"10.1002\/cam4.6103","article-title":"Plasma cell myeloma with RAS\/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis","volume":"12","author":"Li","year":"2023","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.lrr.2026.100615_bib0012","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5045\/br.2020.2020137","article-title":"KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute","volume":"55","author":"Kim","year":"2020","journal-title":"Blood Res."},{"issue":"Supplement 1","key":"10.1016\/j.lrr.2026.100615_bib0013","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1182\/blood-2021-147400","article-title":"Disease characteristics of multiple myeloma involving BRAF mutations","volume":"138","author":"Shehab","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lrr.2026.100615_bib0014","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2013-05-504340","article-title":"Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy","volume":"123","author":"Mulligan","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lrr.2026.100615_bib0015","doi-asserted-by":"crossref","first-page":"256","DOI":"10.21320\/2500-2139-2024-17-3-256-265","article-title":"KRAS\/NRAS gene mutations and the efficacy of Bortezomib-based triplet induction therapy in patients with newly diagnosed multiple myeloma","volume":"17","author":"Sergeeva","year":"2024","journal-title":"Clin. Oncohematol. Basic Res. Clin. Pract."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:33:13Z","timestamp":1793043193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048926000555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":15,"alternative-id":["S2213048926000555"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100615","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prognostic value of KRAS, NRAS, and BRAF genes mutations in patients with newly diagnosed multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100615"}}